Clinical Trials Arizona - Join Arizona Research & Medical Studies

Browse Locations United States » Arizona

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: olodaterol; Drug: tiotropium; Drug: tiotropium + olodaterol
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified January 2012
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified February 2012
A Study to See if AZLI (an Inhaled Antibiotic) is Effective in Treating Adults With Non-CF Bronchiectasis - AIR-BX1

Condition: Bronchiectasis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsor: Gilead Sciences
Recruiting - verified June 2011
Ibudilast in the Treatment of Medication Overuse Headache

Condition: Medication Overuse Headache
Interventions: Drug: Ibudilast; Drug: Placebo
Sponsors: University of Adelaide; University of South Australia
Recruiting - verified October 2011
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsor: Cephalon
Recruiting - verified December 2011
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Condition: Chronic Idiopathic Urticaria
Interventions: Drug: omalizumab; Drug: placebo
Sponsor: Genentech
Recruiting - verified August 2011
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium 18mcg daily; Drug: Salmeterol 100mcg daily; Drug: Fluticasone 250mcg daily; Drug: Fluticasone 125mcg daily; Drug: Fluticasone 50mcg daily; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified January 2012